论文部分内容阅读
目的观察联合吸入噻托溴铵和舒利迭(沙美特罗/丙酸氟替卡松)治疗慢性阻塞性肺疾病(COPD)稳定期的疗效。方法我院呼吸科就诊的Ⅲ~Ⅳ级COPD稳定期患者38例,随机分为治疗组和对照组。治疗组在常规治疗基础上给予联合使用噻托溴铵干粉剂(18ug)每日1次和舒利迭(50μg/100μg)每天2次吸入,对照组在常规治疗基础上仅使用噻托溴铵(50μg/100μg)每天1次吸入,治疗3个月。观察治疗前后肺功能并记录临床症状评分。结果治疗组在临床症状、运动耐力较对照组明显改善、因急性发作住院的次数明显低于对照组;治疗组的FEV1、FVC治疗后显著高于对照组(P<0.05)。结论Ⅲ~Ⅳ级COPD稳定期患者联合吸入噻托溴铵和舒利迭,能减少COPD急性发作次数,提高患者肺功能,明显的改善症状与体征,且使用安全,值得在临床上推广应用。
Objective To observe the efficacy of combined inhalation of tiotropium and seretide (salmeterol / fluticasone propionate) in the treatment of chronic obstructive pulmonary disease (COPD) at stable phase. Methods A total of 38 stable COPD patients with grade Ⅲ ~ Ⅳ in our Department of Respiratory Medicine were randomly divided into treatment group and control group. The patients in the treatment group were given inhaled tiotropium (18ug) once daily and seretide (50μg / 100μg) twice daily on the basis of routine treatment. The control group received only tiotropium (50μg / 100μg) inhaled once daily, for 3 months. Observe the pulmonary function before and after treatment and record clinical symptom score. Results The clinical symptoms and exercise endurance of the treatment group were significantly improved compared with the control group. The number of hospitalizations due to acute attack was significantly lower than that of the control group. The FEV1 and FVC of the treatment group were significantly higher than those of the control group (P <0.05). Conclusions Patients with stage Ⅲ ~ Ⅳ stable COPD inhaled tiotropium and seretide can reduce the number of acute exacerbations of COPD, improve pulmonary function, improve symptoms and signs, and are safe to use. It is worth to be popularized in clinic.